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University, Tainan, TaiwanBackground: Hepatitis B virus (HBV) and hepatitis C virus (HCV) infection induces progressive chronic liver diseases
including hepatitis, fibrosis, cirrhosis and hepatocellular carcinoma (HCC). HCC prognosis is poor because it is often diag-
nosed at late stages and incompletely understanding of virus-related HCC progression and the extent of marker variability
among HCC patients. Therefore, development of new strategies that aim to reduce the risk of HCC in patients who are
chronically HBV or HCV infected is an urgent demand.
Materials and Methods: HCC tissue arrays (147-paired specimens) were purchased from Taiwan Liver Cancer Network,
Zhunan and National Cheng Kung University Hospital, Tainan, Taiwan. HBx transgenic mouse model and orthotopic liver
tumorigenesis model in rat were utilized to clarify the relationship between cyclin D1 and autophagy in liver tumorigenesis.
Autophagosomes were purified from liver cancer cells and immunogold-labeled antibody was used to detect cyclin D1 under
the transmission electron microscopy.
Results: Autophagic activity was inversely correlated with cyclin D1 expression and high cyclin D1 expression accompanied
with low autophagic activity correlated with poor overall survival rate in 147-paired HCC patients. Our animal studies
showed that the off-label use drug amiodarone-induced autophagy suppressed liver tumor formation through degradation of
cyclin D1 and inhibition of cell proliferation. Further study revealed that ubiquitinated cyclin D1 was selectively recruited
into the autophagosome by binding with the receptor protein SQSTM1/p62, which is further degraded after fusion with
lysosome. In summary, we are the first to reveal that autophagy regulates cell cycle process by selectively regulation of
cyclin D1 through p62 mediated degradation pathway in HCC.
Discussion: Impaired autophagy in liver is a risk of HCC development, but the knowledge of signaling pathways that
autophagy involved in the liver tumorigenesis is limited. Our in vitro and in vivo studies show that amiodarone-induced
autophagy suppresses liver tumor formation through degradation of cyclin D1. Altogether, activation of autophagic activ-
ity suggests therapeutic opportunities for HCC and amiodarone is a potential anticancer agent against HCC tumorigenesis.http://dx.doi.org/10.1016/j.bgm.2014.09.018
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